The CDF: friend and foe?
November 11, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, CDF, Cancer, NICE, eric low
Few things in my professional life have troubled me more than the Cancer Drugs Fund (CDF) since its inception in …
New chief executive for the International Diabetes Federation
November 11, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing diabetes, petra wilson
The International Diabetes Federation (IDF) has appointed Dr Petra Wilson as its chief executive. Wilson joins IDF from Cisco, where …
BMS abandons hep C, diabetes and neuroscience
November 11, 2013Sales and Marketing BMS, HIV, diabetes, hep C
Bristol-Myers Squibb is admitting defeat in hepatitis C, diabetes and neuroscience and will abandon research in these areas in a …
Bayer submits Eylea in EU for DME
November 8, 2013Sales and Marketing Bayer, DME, EMA, Eylea, FDA
Bayer HealthCare is seeking to extend the licence of its VEGF Trap-Eye, which is already marketed as Eylea in various …
EMA questions Brilinta data
November 8, 2013Sales and Marketing Brilinta, EMA, astrazenca, heart, ticagrelor
The European Medicines Agency is demanding more information from AstraZeneca on its troubled heart pill Brilinta. This rounds off a …
Genticel appoints vice president


November 8, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing genticel, moeller
Biopharma firm Genticel has appointed Dr Gerald Moeller to sit on its supervisory Board as a vice president. Moeller has …
UK to launch DNA database
November 8, 2013Sales and Marketing DNA, UK, crispr, genome
Volunteers prepared to share their DNA with the rest of the world are being sought by scientists in the UK, …
Alzheimer’s drug development ‘must speed up’
November 7, 2013Research and Development, Sales and Marketing Alzheimer's, CEO, drug development
Alzheimer’s drugs cost three times the industry average to produce, according to a new draft report – and the way …
Shire to cut UK research jobs says source
November 7, 2013Research and Development, Sales and Marketing England, Shire, UK, cuts
Rumours are growing that Shire will be cutting dozens of research posts at its R&D centre in Basingstoke, Hampshire. This …
PPRS: thumbs-down from pharma
November 7, 2013Sales and Marketing ABPI, NHS, PPRS, Pfizer, VBP
A missed opportunity for patients, which creates financial problems for smaller companies while stifling life science investment – these are …
Biotec Services expands with new appointments
November 7, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotec services
Clinical trials services firm Biotec Services International is expanding its presence in the US and the UK with three new …
£10 million boost for synthetic biology
November 6, 2013Research and Development, Sales and Marketing Biological, Synthetic, biotech
The Biotechnology and Biological Science Research Council (BBSRC) has put up £10 million which can be accessed by small companies …
PPRS to remain in UK, but drug growth curbed
November 6, 2013Sales and Marketing ABPI, DH, Deepak Khanna, NHS, PPRS
The UK government has announced that the PPRS pricing scheme will largely remain intact, but will have a curb put …
inVentiv Health acquires Catalina Health
November 6, 2013Medical Communications Adheris, catalina, inVentiv Health
Consulting and services company inVentiv Health has acquired a subsidiary of Catalina (Catalina Health) and joined it onto its own …
ImmunoGen stops cancer trial
November 6, 2013Research and Development, Sales and Marketing Cancer, IMGN901, Immunogen, Roche
Roche subsidiary ImmunoGen has abandoned a Phase II trial into small-cell lung cancer (SCLC) after deciding that it was not …
Profil Institute hires former Amylin chief executive
November 6, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amylin, profil institute
Clinical research firm Profil Institute has appointed former Amylin chief executive Dan Bradbury to its Board of directors. “Dan Bradbury …
UK is the go-to place for developing medicines
November 5, 2013Research and Development, Sales and Marketing BIA, Cell Medica, ReNeuron, UK
The BioIndustry Association (BIA) has said that the UK is clearly the must-go-to location for regenerative medicine research and development. …
J&J hit with $2.2 billion fine
November 5, 2013Sales and Marketing J&J, JJ, Janssen, Risperdal, antipsychotic, fine
Johnson & Johnson has admitted promoting its big-selling antipsychotic drug Risperdal off-label, costing the firm $2.2 billion in fines. The …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
